SEATTLE: AI Technology Group Inc. (OTCID: AIPG) said Friday it has filed an amended Form 10 with the U.S. Securities and Exchange Commission and signed a definitive agreement to acquire AVM Biotechnology Inc., a clinical-stage biopharmaceutical company developing a novel cancer therapy.
Under the agreement dated July 31, 2025, a newly formed subsidiary of AI Technology Group will merge with AVM, making AVM a wholly owned subsidiary upon closing. The transaction is subject to customary conditions outlined in the SEC filing. Following the merger, the company plans to change its corporate name and ticker symbol to reflect the combined business, pending regulatory approval.
AVM Biotechnology is advancing AVM0703, a small-molecule drug designed to activate the body’s Reserve Immune System to target cancer and autoimmune diseases. The drug, currently in Phase 2 trials for relapsed/refractory non-Hodgkin lymphoma, has shown no safety signals in 90 patients across multiple programs, including FDA Expanded Access and global Compassionate Use.
The company said AVM0703 offers outpatient administration, room-temperature stability, and does not require cell engineering or radiation. AVM’s research also suggests potential applications in rheumatoid arthritis, diabetes, and infectious diseases.
AVM is led by Dr. Theresa Deisher, a veteran immunologist with over 30 years in drug development at Genentech, Amgen, and Immunex. She holds more than 47 patents and earned her PhD from Stanford University.
To support AVM’s clinical development, AI Technology Group is conducting a private financing of at least $14 million at $2.50 per share. The offering is limited to eligible investors under applicable exemptions.
AI Technology Group is a Nevada-based smaller reporting company. Upon effectiveness of its Form 10, it will become subject to ongoing SEC reporting requirements.